As for approvals, I don't know why we have each country doing its own approvals, instead of international groups that individuals can choose whether they want to trust or not. Are Europeans sufficiently different than Chinese, Indians, Australians, Canadians, Germans or Americans to warrant independent safety approvals?
If they're using different metrics to process approvals, why? Shouldn't the same inputs result in the same outputs?
In reality, approvals are also about politics.
Take Auryxia which is literally ferric citrate. Its used by kidney patients to control phosphorus levels and boost iron. Why did it take so long to get tested and approved as a drug when the formula was "open source" for a long time? Well one company did the time and effort and suddenly it is considered a valuable drug. The value came from proving the safety and efficacy and someone has to be willing to fund it.
The long line of failed drugs are the real issue.
Sure, just the trial might cost that little if it’s an orphan disease, but it’s also ignoring all the other stuff that goes along with running a trial. Things like manufacturing, compliance, data analysis, etc.
When you look at the total cost of R&D for a drug, it’s typically 1/3 for discovery and 2/3 for development (clinical trials).
If your drug is used in any reasonable sized population, development is easily in the hundreds of millions of dollars.
You are correct about the failure rates though.
Why would an insurance company be interested in developing new drugs? Health insurance companies don't lose money if you die.
How do you propose that academic researchers fund their work, all the way through the approval point?
> The drug research is paid for by patients and insured as it stands now, but the FDA/pharma cartel monopolized drug development using patents and the hugely expensive approval process.
Do you think the process is expensive because of the pharma companies, or do you think the pharma companies are the way they are because the process is expensive?
> Now, pharmas are interested in profitable drugs which don't as much cure the diseases but rather allow mainenance of chronic conditions for years and years. Actual effective cures are not a priority.
This is a thing people say, but it's not really true. It'd be great if all you had to do to create more cures was snap your fingers and change the incentive structure. But the fact of the matter is that cures are harder to create. Incremental improvements are easier. So you get more of them. Pharma companies do in fact still cure things when they can, see the recent HepC cure.